UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
Acne affects up to 50 million Americans annually. The last FDA approval of an acne drug with a new MOA occurred nearly 40 years ago
Subscribe To Our Newsletter & Stay Updated
